These results highlight hospitalization as an opportunity to connect patients with IDU-IE to MOUD and preventative care, particularly in rural areas where access to such services may be limited.
Searching for Solutions
Findings suggest that recent SSP use was associated with recent SUD treatment uptake, while recent CLS involvement was not.
Module 1 of the TMP Training Series provides tools, tactics, and strategies you need to improve your communication skills and strengthen your status as a trusted messenger.
The Centers for Medicare and Medicaid Services (CMS) has directed Medicare Administrative Contractors to lift the hold currently in place on some claims with service dates occurring after Oct. 1. This includes telehealth claims that the agency “can confirm are definitively for behavioral and mental health services.” The agency says it will continue to temporarily hold claims for other telehealth services. Many pandemic-era telehealth flexibilities expired Oct.
“Given this landscape, psychiatric pharmacists play a more important role than ever in patient care. Our knowledge, experience, and understanding of other disease states allows us to support the whole patient.” - Dr. Bostwick
The AAPP membership has elected three officers to serve on the 2026-2028 Board of Directors. Assuming their offices effective July 1, 2026, will be Drs. Austin Campbell, Julie Cunningham and Bethany DiPaula. These 3 new members will join Drs. Jolene Bostwick, Kelly Gable, Suzanne Harris and Danielle Stutzman on the Board for 2026-2027.
No summary available
It is time to update the directory of Psychiatric Pharmacy Residency Programs. We want your help to self-identify if you participate in residencies. By adding your information to the site, you can raise the visibility of your program among those with a strong interest in psychiatric pharmacy. NEW fields allow you to include your recruitment open-house information.
The CMS Innovation Center recently released evaluation reports and publications related to the MOM Model, a patient-centered service delivery model that aims to improve the quality of care for pregnant and postpartum Medicaid beneficiaries with opioid use disorder (OUD) and their infants. The reports acknowledge that MOM Model beneficiaries faced complex and overlapping health, behavioral and social challenges that demanded flexible, trauma-informed care.
No summary available
The value and impact of psychiatric pharmacists takes center stage in this HealthWell Foundation feature article.
In early November, AAPP will be launching a 5.5 hour educational series on clozapine. Grant funded in partnership with the Schizophrenia & Psychosis Alliance, this program seeks to educate clinicians and expand the use of clozapine. News of this grant has also promoted the role of psychiatric pharmacists as seen in this article on HealthWell Foundation’s website. HealthWell is a non-profit that provides financial assistance for insurance and medications for illnesses such as schizophrenia.
AAPP members Michelle Geier, PharmD, APh, BCPP, FAAPP; Michelle Colvard, PharmD, BCPP; and Rebecca Hoss, PharmD, BCPP represented AAPP and psychiatric pharmacy in presenting a session on the important role of psychiatric pharmacists in treating and engaging patients with MOUD. Speakers detailed their practice models and the significant impact they make as psychiatric pharmacists in various settings including in public health, an outpatient SUD clinic, and a hospital system.
AAPP members Michelle Geier, PharmD, APh, BCPP, FAAPP; Michelle Colvard, PharmD, BCPP; and Rebecca Hoss, PharmD, BCPP represented AAPP and psychiatric pharmacy in presenting a session on the important role of psychiatric pharmacists in treating and engaging patients with MOUD. Speakers detailed their practice models and the significant impact they make as psychiatric pharmacists in various settings including in public health, an outpatient SUD clinic, and a hospital system.
Persisting high rates of mental health disorders in patients in opioid agonist treatment—Results from a 6-year longitudinal study
Use of stigmatizing language related to substance use disorders in media: A systematic review
Medications for Opioid Use Disorder in County Jails — Outcomes after Release
This study provides the first evidence that CM use in real-world health care settings is associated with reduced risk of mortality.
ASAM has expanded its benzodiazepine tapering resource suite to support clinicians and patients.
No summary available
AAPP supports access to MOUD and defining OUD as a treatable medical condition with a biological basis often associated with a history of trauma. Use AAPP’s policy brief to advocate for this gold-standard treatment.
AAPP supports access to behavioral interventions and stimulant treatment for youth with functionally impairing symptoms of ADHD. Use AAPP’s policy brief to advocate for this gold-standard treatment.
AAPP supports the availability of SSRIs as treatment option for moderate to severe symptoms of perinatal depression and anxiety with appropriate weighing of all risks and benefits. Use AAPP’s policy brief to advocate for this gold-standard treatment.
AAPP supports access to antidepressants for youth with moderate to severe symptoms of depression, anxiety, or OCD and reconsideration of the suicide boxed warning. Use AAPP’s policy brief to advocate for this gold-standard treatment.
AAPP supports access to mood stabilizers, including lithium, for the treatment of bipolar disorder. Use AAPP’s policy brief to support your own advocacy for this gold-standard treatment (member only resource).